The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / No Clear Connection Between Inflammation & Disease Progression in AS

No Clear Connection Between Inflammation & Disease Progression in AS

October 1, 2010 • By Kathy Holliman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

It has been long understood and well accepted that inflammation and structural damage are tightly connected in rheumatoid arthritis and that the degree of structural damage will be controlled if the inflammation is controlled.

You Might Also Like
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
  • ACR/ARHP Annual Meeting 2012: Spondylarthritis Criteria Changing Landscape of the Disease
  • EULAR 2015: Emerging Concepts, Treatments for Axial Spondyloarthritis
Explore This Issue
October 2010
Also By This Author
  • 2014 ACR/ARHP Annual Meeting: Diagnosis, Management of Sarcoidosis in the Heart, Central Nervous System

Eric M. Ruderman, MD, associate professor of medicine at Northwestern University Feinberg School of Medicine in Chicago, moderated the session on the apparent disconnect between inflammation and disease progression in ankylosing spondylitis (AS) at the 2009 ACR/ARHP Annual Scientific Meeting in Philadelphia.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Once TNF [tumor necrosis factor] blockers entered the arena, the link between inflammation and what was occurring structurally was found not to be so tight. Even though we are treating the symptoms, we may not in the long run be having any impact on the structural outcome of the disease,” he said.

A chronic inflammatory disease, AS preferentially affects the axial structure, with peripheral arthritis and extraarticular manifestations common. Inflammation of the enthesis is also common, with insertion of bone into tendons and ligaments, Dr. Ruderman said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Effect of TNF Agonist Therapy

Desiree M.F.M. van der Heijde, MD, PhD, professor of rheumatology at Leiden University Medical Center in Leiden, The Netherlands, reviewed recent research that has investigated the efficacy of TNF blockers on progression of structural damage in AS. One trial used etanercept therapy; another, infliximab; and the third, adalimumab. In the trial with etanercept, Davis et al showed a sustained response in improvement of signs and symptoms of AS in patients receiving twice weekly doses of the agent.1 The Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) trial examined efficacy of infliximab versus placebo and found that the therapy decreased spinal inflammation as assessed by MRI.2

The two-year results of the Adalimumab Trial Evaluating Long-Term Efficacy and Safety in Ankylosing Spondylitis (ATLAS) trial showed that adalimumab reduced the signs and symptoms of AS and induced partial remission for up to two years. As with etancercept and infliximab, the agent improved patient quality of life.3

Dr. van der Heijde reviewed results of two-year follow-up studies that compared radiographic progression between patients enrolled in those trials and those enrolled in the Outcome Assessments in Ankylosing Spondylitis International Study (OASIS). The OASIS trial began in 1996 at four European centers and is a longitudinal observational study. Patient use of nonsteroidal antiinflammatory drugs was comparable in all trials.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

One of these follow-up studies compared progression in structural damage between patients enrolled in either the Canadian AS study or the ATLAS trial and those in the OASIS cohort. In the Canadian AS study and in ATLAS, patients had been treated with the TNF blocker adalimumab; patients in the OASIS trial had not received a TNF blocker. Radiographic progression in the spine at baseline and at two years was measured using the modified Stoke AS Spine Score (mSASSS) method.

Once TNF blockers entered the arena, the link between inflammation and what was occurring structurally was found not to be so tight. Even though we are treating the symptoms, we may not in the long run be having any impact on the structural outcome of the disease.

—Eric M. Ruderman, MD

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis, Spondyloarthritis, Systemic Inflammatory Syndromes Tagged With: Ankylosing Spondylitis, inflammation, RA, Rheumatoid arthritis, therapy, tumor necrosis factorIssue: October 2010

You Might Also Like:
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
  • ACR/ARHP Annual Meeting 2012: Spondylarthritis Criteria Changing Landscape of the Disease
  • EULAR 2015: Emerging Concepts, Treatments for Axial Spondyloarthritis
  • Researcher Reflects on the Development of the Disease Activity Score

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)